3092 – CRISPR OPTIMIZATION TO SCREEN FOR GENES THAT REGULATE FATE SPECIFICATION OF PRIMARY HUMAN HEMATOPOIETIC PROGENITORS

Rubia Isler Mancuso,Evrett Thompson,Lin Wang,Diane S. Krause

DOI: https://doi.org/10.1016/j.exphem.2023.06.199

IF: 3.249

2023-01-01

Experimental Hematology

Abstract:Although megakaryocytic and erythroid maturation have been studied, little is known about the molecular mechanisms underlying megakaryocytic-erythroid progenitor (MEP) fate specification. Addressing this question, I proposed to perform a CRISPR screen to interrogate a panel of genes for their ability to regulate MEP fate. As primary human cell numbers are limited, the number of genes to be analyzed is ∼80 to allow 3 gRNAs per gene with at least 50 cells per gRNA and estimating a transduction efficiency of ∼30% to assure 1 gRNA per cell (1 gene per 450 cells). For this screen, I am optimizing the use of guide swap (Ting et al., 2018), that allows primary cell editing by transducing cells with a library of gRNAs using lentivirus followed by transfection with Cas9 protein precomplexed to nontargeting gRNA (ntRNA). Once inside a cell, the gRNA ‘swaps’ with the ntRNA to efficiently edit the cell. I am using CROPseq (Datlinger et al., 2017) vector with an mCherry fluorescent reporter that allows the gRNA sequence within a transduced cell to be detected along with the total RNA by scRNAseq. Transfection of progenitors with a CD45-targeting single guide RNA (sgRNA) precomplexed with Cas9-GFP yields ∼38% CD45 negative cells within 4 days. Simultaneously, lentiviral transduction using the mCherry fluorescent reporter was performed. We found that pretreatment with AZD7648, a DNA-PK inhibitor, enhances CRISPR-induced modification. Using our optimized approaches AZD7648 pretreatment enhanced post-transfection CD45 negative cells from 17% using Cas9 alone to 30%. A small library (5 nontargeting, 3 positive controls and 5 interrogated genes) has been cloned into the CROPseq-mCherry vector resulting equal guide representations. Thus, I am progressing in a stepwise manner towards the goal of performing a larger scale screen of genes that regulate MEP fate specification.

medicine, research & experimental,hematology